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Abstract
Objectives
In this replication-and-extension study, we tested whether depressive symptoms, neuroti-
cism, and allostatic load (multisystem physiological dysregulation) were related to lower
baseline cognitive ability and greater subsequent cognitive decline in older adults, and
whether these relationships were moderated by the E4 allele of the apolipoprotein E
(APOE) gene. We also tested whether allostatic load mediated the relationships between
neuroticism and cognitive outcomes.
Methods
We used data from the Lothian Birth Cohort 1936 (n at Waves 1–3: 1,028 [M age = 69.5 y];
820 [M duration since Wave 1 = 2.98 y]; 659 [M duration since Wave 1 = 6.74 y]). We fitted
latent growth curve models of general cognitive ability (modeled using five cognitive tests)
with groups of APOE E4 non-carriers and carriers. In separate models, depressive symp-
toms, neuroticism, and allostatic load predicted baseline cognitive ability and subsequent
cognitive decline. In addition, models tested whether allostatic load mediated relationships
between neuroticism and cognitive outcomes.
Results
Baseline cognitive ability had small-to-moderate negative associations with depressive
symptoms (β range = -0.20 to -0.17), neuroticism (β range = -0.27 to -0.23), and allostatic
load (β range = -0.11 to 0.09). Greater cognitive decline was linked to baseline allostatic
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load (β range = -0.98 to -0.83) and depressive symptoms (β range = -1.00 to -0.88). How-
ever, APOE E4 allele possession did not moderate the relationships of depressive symp-
toms, neuroticism and allostatic load with cognitive ability and cognitive decline.
Additionally, the associations of neuroticism with cognitive ability and cognitive decline were
not mediated through allostatic load.
Conclusions
Our results suggest that APOE E4 status does not moderate the relationships of depressive
symptoms, neuroticism, and allostatic load with cognitive ability and cognitive decline in
healthy older adults. The most notable positive finding in the current research was the strong
association between allostatic load and cognitive decline.
Introduction
Cognitive aging is an increasingly important public health issue [1]. It is therefore crucial that
we aim to improve our understanding of the risk factors for negative cognitive outcomes in
old age and how these risk factors interact, so that we can work towards accurately identifying
and optimally treating those at higher risk of harmful cognitive aging.
Three such risk factors are the E4 allele of the apolipoprotein E (APOE) gene, depression
and neuroticism. People with major depressive disorder tend to have higher than average neu-
roticism [2], so the relationships between neuroticism and cognitive outcomes will tend to
overlap with the relationships between depression and cognitive outcomes. Studying both sets
of relationships is valuable, because neuroticism is a broader construct than depression. It
comprises several facets, including anxiety, hostility, self-consciousness and vulnerability to
stress [3].
The relationships of APOE E4, depressive symptoms and neuroticism with
cognitive ability
The APOE E4 allele, depression and neuroticism have each been found to have adverse associa-
tions with contemporaneously measured cognitive ability and subsequent cognitive decline.
Possession of the E4 allele of the APOE gene has been linked to higher risk of late-onset Alzhei-
mer’s disease [4] as well as lower cognitive ability [5] and greater cognitive decline [6] in non-
clinical groups of older adults. Additionally, depression at a young age seems to increase risk
for dementia, and in old age, depression may sometimes be prodromal of dementia [7]. In cog-
nitively healthy individuals, depressive symptomatology and neuroticism have each been
related to worse cognitive ability and greater cognitive decline [8–10]. Also, APOE genotype
has been linked to the variability of depressive symptomatology and spatial reasoning within
pairs of monozygotic twins [11]. This result suggested that for those outcomes, APOE genotype
may moderate the effects of some environmental variables.
APOE E4 moderation of the relationships depressive symptoms and
neuroticism have with cognitive ability
Recent research has investigated whether APOE genotype moderates the associations of
depression and neuroticism with cognitive ability and decline such that they are stronger in E4
allele carriers. If these moderating effects were confirmed, this would have implications for the
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treatment of older depressed and neurotic people and help us to understand some of the mech-
anisms underlying these relationships. Longitudinal studies have found that depression
increases dementia and mild cognitive impairment risk more in E4 carriers than in E4 non-
carriers [12–16]. Plus, studies using cognitive impairment screeners to measure cognitive abil-
ity have reported that depressive symptoms have a stronger association with cognitive ability
and decline in E4 allele carriers [17, 18]. However, cognitive impairment screening tests are
known to exhibit ceiling effects when administered in non-impaired populations [19, 20]. As
such, to test the moderation by E4 status (carrying vs. not carrying at least one E4 allele) in
relation to the full range of healthy cognitive ability, it is preferable to use finer-grained cogni-
tive tests. Only one of three studies that used multiple, more challenging cognitive tests to mea-
sure cognition reported that depressive symptoms were more strongly related to cognition in
E4 carriers ([21], cf. [22–24]). Regarding neuroticism, in the Ginkgo Evaluation of Memory
sample neuroticism has a greater negative association with cognitive ability [25] and subse-
quent cognitive decline [26] in E4 carriers. In the Victoria Longitudinal Study sample, how-
ever, APOE E4 status did not moderate the relationships of neuroticism with baseline
declarative memory and subsequent decline in declarative memory [24]. Furthermore, a cross-
sectional study of 172 non-demented older adults based in Rochester, New York, USA, found
that there was overall APOE-by-neuroticism interaction when predicting scores on five cogni-
tive domains, although the only specific domain for which the interaction was statistically sig-
nificant was attention [27].
Viewing the APOE-by-neuroticism interaction within an allostatic load
framework
Dar-Nimrod et al. put forward that the interaction between neuroticism and APOE E4 status
can be thought of within "an allostatic load framework" ([25], p. 1148). Allostatic load (AL)
refers to the accumulation of damage to the body from the dysregulation of physiological sys-
tems [28]. AL is typically operationalised by calculating summary scores for participants using
biomarker data from multiple physiological systems, such as the metabolic, neuroendocrine,
cardiovascular and immune systems [29]. Ideally, AL summary scores would be calculated
using many biomarkers from a wide range of physiological systems, including both primary
mediators of stress responses and secondary outcome biomarkers whose levels change in
response to primary mediators’ levels. Most commonly, AL summary scores are sums of at-
risk biomarkers, where risk is indicated by sample quantiles or clinical thresholds [30]. A com-
parative study found that scoring methods with higher criterion validity were those that
retained continuous measurement of the biomarkers and/or incorporated risk at both high
and low levels of biomarkers [31]. More recently, some researchers have generated scores
through modeling AL as a latent factor that causes AL biomarker values [32, 33,], although this
method has been called into question based on the assumptions underlying these models [34].
Specifically, Dar-Nimrod et al. [26] posited that this interaction may function through
increased hypothalamic–pituitary–adrenal (HPA) axis activity, with "inflammatory and meta-
bolic processes" ([25], p. 1152) also possibly playing a role. The hypothesis put forward by
Dar-Nimrod et al. is directly testable using moderated-mediation models [35]. In such a
model, the effect of neuroticism on cognitive ability and decline would be partially mediated
through physiological dysregulation, and the second stage of this mediation process, from
physiological dysregulation to cognition, would be moderated by APOE E4 status.
Some previous research reports findings consistent with Dar-Nimrod et al.’s [25, 26] suppo-
sition. Individuals with high neuroticism tend to display maladaptive HPA axis activity [36],
have higher inflammation [37, 38,], and be at higher risk of metabolic syndrome [39]. A recent
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study found that higher neuroticism was related to higher AL, although higher AL did not pre-
dict change in neuroticism over a four-year period [40]. Studies of older adults have reported
that higher cortisol levels more strongly predict decrements in contemporaneously measured
cognitive ability [41] and subsequent cognitive decline [42] in APOE E4 carriers. Additionally,
higher AL has been linked to greater depressive symptomatology [43] as well as worse cogni-
tive ability [31, 44, 45] and subsequent decline [46–48].
The present study
In the present study, we tested whether the effects of depressive symptoms, neuroticism and
AL on baseline general cognitive ability and subsequent general cognitive decline were moder-
ated by APOE E4 possession. Specifically, we tested the following sequence of research
questions:
1. Do APOE E4 non-carriers and carriers differ in their baseline cognitive ability and in their
levels of subsequent change in cognitive ability?
2. Are baseline depressive symptoms, neuroticism and allostatic load related to baseline cogni-
tive ability and subsequent change in cognitive ability?
3. Are the relationships of baseline depressive symptoms, neuroticism and allostatic load with
baseline cognitive ability and subsequent cognitive change moderated by APOE status?
4. Are the relationships of baseline neuroticism with baseline cognitive ability and subsequent
cognitive change mediated by allostatic load?
5. Are these mediated effects moderated by APOE status?
Previous studies using this sample have tested some of the main effects of the present study,
such as the associations of APOE genotype [49, 50], time [36, 51], depressive symptoms [52]
and AL [45] with cognitive ability. However, this is the first study using this sample to test the
APOE moderation of the relationships of depressive symptoms, neuroticism and allostatic load
with cognitive outcomes, as well as the first to test the association of AL with change in cogni-
tive ability during older age.
Methods
Participants
The sample used was the Lothian Birth Cohort 1936 (LBC1936). On June 4, 1947, almost all
school children in Scotland born in 1936 took the Moray House Test No. 12, a validated intelli-
gence test, as part of the Scottish Mental Survey 1947 [53]. The LBC1936 study recruited sur-
viving Scottish Mental Survey 1947 participants living in the Lothian region (the City of
Edinburgh and its surrounding area) to investigate cognitive aging. The LBC1936 study
design, including the recruitment and testing of the sample, has been detailed in two cohort
profiles [54, 55].
Briefly, data was used from the LBC1936 baseline wave, and follow-up waves approximately
three and seven years post-baseline. Data was collected for LBC1936 Wave 1 in 2004–2007
(N = 1091 [543 females, 548 males]; M [SD] age = 69.5 [0.8] y), for Wave 2 in 2007–2010
(n = 866 [418 females, 448 males]; M [SD] age = 72.5 [0.7] y; M [SD] time since Wave 1 data
collection = 2.98 [0.28] y), and for Wave 3 in 2011–2013 (n = 697 [337 females, 360 males]; M
[SD] age = 76.3 [0.7] y; M [SD] time since Wave 1 data collection = 6.74 [0.31] y).
Ethical permission for the LBC1936 study protocol was obtained from the Multi-Centre
Research Ethics Committee for Scotland (MREC/01/0/56) and from the Lothian Research
APOE E4 does not moderate links with cognitive ability in the LBC1936
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Ethics Committee (LREC/2003/2/29). The research was carried out in compliance with the
Helsinki Declaration. All subjects gave written, informed consent.
The number of participants with each genotype was: E2/E2, 5; E2/E3, 120; E2/E4, 23; E3/
E3, 597; E3/E4, 262; E4/E4, 21. APOE in the current sample has previously been shown to be in
Hardy-Weinberg equilibrium (p = 0.62) [49] All study participants were white. The number of
participants who self-reported having dementia was 10 in total: two at Wave 2 and nine at
Wave 3, which included one of the two at Wave 2.
Measures
Cognitive test, age and medical condition data came from LBC1936 Waves 1, 2 and 3. Depres-
sive symptoms, neuroticism and allostatic load data came from LBC1936 Wave 1.
APOE genotyping
Participants’ DNA was isolated from whole blood samples. To determine which APOE alleles
individuals possessed, the single nucleotide polymorphisms rs7412 and rs429358 were geno-
typed using TaqMan assays (Applied Biosystems, Carlsbad, CA, USA). This was done by the
Wellcome Trust Clinical Research Facility Genetics Core at the Western General Hospital in
Edinburgh.
General cognitive ability
The full cognitive test battery administered to the participants was detailed in the LBC1936
cohort profile [54]. The present study used data from the following five subtests of the Wechs-
ler Adult Intelligence Scale IIIUK [56]: Digit Symbol Coding, a processing speed test where par-
ticipants enter symbols based on a provided number-symbol code; Block Design, a reasoning
test where participants must use blocks to duplicate a given design; Symbol Search, a process-
ing speed test where participants must indicate whether rows of symbols include either of two
target symbols; Letter-Number Sequencing, a working memory test that requires ordered
recall of unordered numbers and letters; and Matrix Reasoning, where participants must select
the correct piece to complete a patterned matrix. Collectively, these tests primarily assess
higher-order executive functions, which mainly tap the frontal lobe.
Cognitive impairment screening. The Mini Mental State Examination (MMSE) [57] was
used as a test of global cognitive status. It is a brief measure that was designed to identify cogni-
tive impairment and assess its extent [57]. The MMSE has been part of the LBC1936 protocols
since the outset as a screening test for dementia onset.
Depressive symptoms. The seven-item depression subscale of the Hospital Anxiety and
Depression Scale (HADS-D) [58] was used to measure depressive symptoms. Item-level data
was unavailable, so instead of depressive symptoms being modeled as a latent factor, observed
subscale scores were used.
Neuroticism. The 10-item emotional stability subscale of a 50-item Big Five factor mark-
ers scale [59] from the International Personality Item Pool (IPIP) [60] was reverse scored to
serve as a measure of neuroticism. We modelled neuroticism as a latent variable using item
parcels, which are sums of different item responses [61]. We used item parcels to normalize
the distributions of manifest variables and to facilitate model fitting by keeping the model
compact, with as few variables as were required. Primary analyses used three item parcels, each
of which contained items about different facets of neuroticism so that each parcel was repre-
sentative of the broader domain of neuroticism. The parcels which were formed from three
(items 4, 34, 49), four (9, 14, 29, 39) and three (19, 24, 44) items respectively. An individual’s
score on each parcel was the mean score of the items they answered, or coded as missing if
APOE E4 does not moderate links with cognitive ability in the LBC1936
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they had not answered half or more of the parcel’s items. Neuroticism was then modeled as a
latent variable, the common cause of the variance shared by the item parcels. This enabled us
to test the measurement invariance of neuroticism across groups (see Statistical Analysis
section).
Allostatic load. AL scores were mean absolute z scores from nine biomarkers: albumin;
C-reactive protein (CRP); fibrinogen; glycated haemoglobin (HbA1c); high-density lipopro-
tein ratio (HDL ratio or HDLR); triglycerides; body mass index (BMI); systolic blood pressure
(SBP); and diastolic blood pressure (DBP; see S2 Appendix for descriptive statistics for the bio-
markers). The z score method has previously performed well in a comparison of AL measure-
ment methods [31]. For each biomarker, z scores were calculated using the standard formula,
where the variable mean is subtracted from the observed values to centre the mean at zero, and
then the values are divided by the variable standard deviation to standardise the variable by
giving it a standard deviation of 1. To normalize their distributions, before biomarkers were z
scored and summed, the following biomarkers were log transformed: CRP; fibrinogen;
HbA1c; triglyceride; BMI; SBP; and DBP. For all biomarkers we used except HDL ratio, risk
can be indicated with high or low values, so we used absolute z scores, which indexed how far
values were from the sample mean. Risk is indicated with only a high HDL ratio, so z scores
below zero on this biomarker were changed to zero before the biomarker z scores were com-
bined to create the AL scores. AL scores were not computed for the 27 participants who had
missing data on half or more of these biomarkers.
The following biomarkers were measured using blood samples: albumin; CRP; fibrinogen;
HbA1c; HDLR; and triglycerides. Albumin was measured using Vitros ALB slides, with col-
ourimetric tests conducted using the Vitros Fusion 5.1 FS and Vitros 4600 Chemistry Systems.
CRP was measured with the OrthoFusion 5.1 F.S. analyser using dry immuno-rate slides
(Vitros Chemistry Products CRP slides, Ortho Clinical Diagnostics, Buckinghamshire, UK).
Fibrinogen was measured with an automated Clauss assay (TOPS coagulator, Instrumentation
Laboratory, Warrington, UK). Non-fasting HbA1c was measured with an Adams HA-8160
HbA1c analyser, which uses a high performance liquid chromatography method. High-density
lipoprotein and total cholesterol were measured using the Abbott Architect c16000 and the
HDL ratio was calculated by dividing total cholesterol by high-density lipoprotein. Triglycer-
ides were also measured using the Abbott Architect c16000.
BMI was computed by dividing participants’ weight in kilograms by their squared height in
meters. SBP and DBP values were the mean of three sitting readings.
Medical history and medication status. During a medical interview at the time of the
cognitive assessment and blood sampling, participants’ medical history was taken and they
were asked to provide information on their current prescription medications. Adjustments
were made to raw biomarker values where participants were taking drugs related to AL (anti-
hypertensive, lipid-lowering, insulin and other diabetes medications) [62]. For those taking
antihypertensives, SBP was increased by 10mmHG and DBP by 5mmHG. For those taking
statins, total cholesterol was increased by 1.8mmol/l and CRP by 0.02mg/dl. Finally, for those
taking insulin or other diabetes medication, HbA1c was increased by 1%.
Covariates. To control for their influence, sex, age at the day of assessment at each wave,
and a count of medical conditions at each wave were used as covariates. Participants self-
reported medical condition information during structured interviews. The following medical
conditions were included in the count: arthritis; problems with blood circulation; history of
cardiovascular disease; dementia; diabetes; high blood pressure; high cholesterol; leg pain
when walking or in bed at night; cancer; Parkinson’s disease; history of stroke; thyroid disor-
der; and an additional point was added if a participant had another medical condition not
APOE E4 does not moderate links with cognitive ability in the LBC1936
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specifically asked about. In response to a reviewer request, we also included years of education
(collected at Wave 1) as a covariate and present results of this analysis in S4 Appendix.
Statistical analysis
The R software environment (Version 3.2.0; [63]) was used for data importing, data manage-
ment, data cleaning, plotting distributions, calculating descriptive statistics, calculating AL
scores and facilitating model fitting. These tasks were aided by the R packages psych (Version
1.5.4; [64]), Hmisc (Version 3.16–0; [65]), memisc (Version 0.97; [66]), likert (Version 1.2;
[67]), plyr (Version 1.8.3; [68]) and MplusAutomation (Version 0.6–3; [69]).
Second-order multiple group latent growth curve models (MGLGCMs) using groups based
on APOE genotype were fitted to answer the study’s research questions. Fig 1 is a diagram of
the unconditional LGCM in one group. The observed cognitive test scores loaded on a latent
factor representing cognitive ability at their respective waves, and the three measurements of
the general cognitive ability factor loaded on the latent intercept and slope growth factors. The
intercept growth factor represented initial level of ability and the slope growth factor repre-
sented linear change in ability over time. The mean of the intercept represents the average ini-
tial level of ability while the mean of the slope represents the average linear change in ability
over time. The variances of the growth factors indicate how much variability there is around
these means. We tested whether the intercept and slope means were related to neuroticism,
depressive symptoms and allostatic load, and whether these relationships varied across geno-
typic groups.
The intercept growth factor’s loadings were fixed at 1.0. The slope growth factor’s loadings
were fixed at values calculated to reflect the differences in mean ages between waves of assess-
ment. The slope loadings were therefore fixed at 0.0, 1.0 and 2.27 on the general cognitive abil-
ity factors from Waves 1, 2 and 3 respectively.
Grouping variables. Primary analyses used groups of APOE E4 carriers and non-carriers.
Following Dick et al. [70], all analyses were also conducted using groups of individuals possess-
ing specific genotypes. The sample size of most genotypes was prohibitively small, so groups
were formed of individuals with the two most common APOE genotypes, E3/E3 and E3/E4.
Measurement models and covariates. The measurement invariance of general cognitive
ability across time and across groups and the measurement invariance of neuroticism across
groups was then tested to establish the equivalence of the latent variables used for model esti-
mation. After this, the main effect of APOE E4 was assessed by testing the invariance of the
growth factor means across groups. For full details of these models, see S1 Appendix.
Next, covariates were added to the models. Sex was modeled as a time-invariant covariate
predicting both growth factors. Age at each wave (coded in years and centered at 67) and num-
ber of medical conditions at each wave were modeled as time-varying covariates predicting all
cognitive ability manifest variables at their respective waves. All covariances between covari-
ates were freely estimated in each group, except for covariances between different time-varying
covariates from different waves, which were fixed at zero. All estimated parameters involving
covariates were freely estimated across groups. This effectively also controlled for gene-by-
covariate interactions, in line with current methodological recommendations [71].
Effects of depressive symptoms, neuroticism and AL. Separate models were fitted in
which depressive symptoms, neuroticism and AL predicted the cognitive ability intercept and
slope. Additionally, a mediation model was fitted in which neuroticism predicted the growth
factors both directly and through AL.
Model testing. The moderation of each effect of interest (i.e. the effects of depressive
symptoms, neuroticism and AL on the initial level of cognitive ability [intercept] and the
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subsequent linear change in cognitive ability [slope]) was tested by comparing the fit of two
models: one with the regression for the effect freely estimated in both the group of E4 non-car-
riers and the group of E4 carriers, one with it constrained to equality across groups. A signifi-
cant decrement in fit in the latter model would indicate moderation.
Fig 2 illustrates the growth factors and predictors of interest for the models in one group.
Note that the covariance between the intercept and slope has been omitted for clarity. In this
figure, for example, paths a and b from depressive symptoms to the growth factors were only
in the three models testing the (moderation of the) effects of depressive symptoms: one with
both paths freely estimated across groups; one with the path to the intercept jointly estimated/
constrained to equality across groups and the path to the slope freely estimated across groups;
and one with the path to the slope jointly estimated/constrained to equality across groups and
the path to the intercept freely estimated across groups. The (moderation of the) effects of neu-
roticism (paths c and d) and AL (paths e and f) were tested using the same setup, with the only
paths included being c and d for the neuroticism models and e and f for AL models. Finally,
the mediation models contained paths c-f. In the mediation model, it was the second stage of
the model, from AL to cognitive ability and decline that was tested for moderation (paths e
and f).
Covariances between predictors and covariates were freely estimated in each group, except
those between predictors and age at the latter two waves, which were fixed at zero.
Full information maximum likelihood (FIML) estimation in Mplus Version 7.31 [72] was
used to fit all SEMs. We assumed that missing data was missing at random, a condition under
which FIML estimation performs well [73].
Mardia’s tests indicated that input variables were not multivariate normally distributed, so
robust standard errors (SEs) were computed for all models using a sandwich estimator. As
robust SEs were calculated, Satorra-Bentler scaled chi-square difference tests for nested models
based on their loglikelihoods [74, 75] were used to compare models, with p .05 indicating a
statistically significant difference in fit. The SEs for tests of the indirect effect in mediation
models were calculated using the delta method.
Fig 1. Path diagram of the unconditional LGCM for general cognitive ability in one group. Variances, residual covariances and estimates excluded for clarity.
The timepoint of each item is indicated here by the factor the item loads on. I = intercept. S = slope. g_W1 = Wave 1 general cognitive ability. g_W2 = Wave 2
general cognitive ability. g_W3 = Wave 3 general cognitive ability. BD = Block Design. DS = Digit Symbol Coding. LN = Letter-Number Sequencing.
MR = Matrix Reasoning. SS = Symbol Search.
https://doi.org/10.1371/journal.pone.0192604.g001
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Robustness checks. As a check on the robustness of our primary operationalization of
neuroticism, models were also fitted using an alternative parceling scheme for neuroticism
that had parcels comprised of items that were also included in facet scales for depression
(items 19, 39, 49), anxiety (4, 9, 14, 24) and anger (29, 44) in an IPIP representation of the
NEO Personality Inventory–Revised [76]. Plus, as a check on the influence that pathological
cognitive aging may have had on results, additional models were fitted after excluding partici-
pants who scored below 24 on the MMSE (13 E4 non-carriers, 12 E4 carriers; 10 with the E3/
E3 genotype, 7 with the E3/E4 genotype) and/or with those who reported having had a stroke
or having dementia or Parkinson’s disease also excluded (92 E4 non-carriers, 62 E4 carriers; 82
with the E3/E3 genotype, 34 with the E3/E4 genotype). The 23v24 cutoff we used for the
MMSE is common when screening for cognitive impairment [77].
Models controlling for education. Lastly, we fitted models that added years of education
as a covariate predicting the cognitive ability intercept and slope, thus controlling for the
effects of education (see S4 Appendix).
Results
For descriptive statistics for the whole genotyped sample as well as for the groups of E4 non-
carriers and E4 carriers, see Table 1. For raw biomarker descriptive statistics, descriptive statis-
tics for the secondary grouping with groups of those with the E3/E3 and E3/E4 genotypes, and
Fig 2. Structural model paths for the various hypothesis-testing models. Covariates, variable variances and the
covariance between the intercept and slope omitted for clarity. Lower case letters are the path names referred to in text.
DS = depressive symptoms. N = neuroticism. AL = allostatic load. I = cognitive ability intercept. S = cognitive ability slope.
https://doi.org/10.1371/journal.pone.0192604.g002
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correlations within each group, see S2 Appendix. Results from the models using both group-
ings were similar, so here we present only the models from the more powerful analyses using
the groups of E4 non-carriers and E4 carriers. For the results from models using groups of
those with the E3/E3 and E3/E4 genotypes, see S3 Appendix. For the full measurement model
results, see S1 Appendix.
Unconditional latent growth curve models
In initial models, the slope growth factor had a negative residual variance. The slope growth
factor variance was therefore fixed at zero. Note that models with this restriction fitting well
suggested that cognitive change in the sample was relatively homogeneous.
Table 1. Descriptive Statistics for Groups of APOE E4 Non-carriers and Carriers.
Variable n M SD Skew Kurtosis
both
groups
no E4
group
E4
group
both
groups
no E4
group
E4
group
both
groups
no E4
group
E4
group
both
groups
no E4
group
E4
group
both
groups
no E4
group
E4
group
Block Design W1 1023 719 304 33.73 33.99 33.13 10.30 10.24 10.42 0.27 0.28 0.25 -0.24 -0.17 -0.42
W2 818 573 245 33.50 33.79 32.84 33.50 10.19 9.75 0.47 0.42 0.59 0.08 0.08 0.08
W3 653 453 200 32.08 32.67 30.75 32.08 9.80 10.41 0.30 0.30 0.37 0.25 0.23 0.32
Digit Symbol W1 1023 717 306 56.63 57.02 55.70 13.00 13.14 12.62 0.04 0.03 0.05 -0.24 -0.23 -0.29
W2 816 572 244 56.34 56.65 55.60 12.41 12.66 11.82 0.05 0.07 -0.05 -0.19 -0.37 0.27
W3 647 450 197 53.70 54.84 51.10 12.92 12.34 13.85 -0.10 -0.12 0.04 -0.09 0.02 -0.29
Letter-Number
Sequencing
W1 1017 716 301 10.90 11.03 10.62 3.16 3.20 3.04 0.14 0.14 0.09 0.08 0.00 0.25
W2 818 574 244 10.91 10.94 10.83 3.08 3.13 2.95 0.24 0.24 0.21 0.30 0.14 0.71
W3 649 454 195 10.46 10.57 10.22 2.99 3.03 2.86 0.18 0.28 -0.11 0.35 0.49 -0.28
Matrix
Reasoning
W1 1024 720 304 13.46 13.69 12.91 5.11 5.14 5.00 -0.02 -0.07 0.10 -1.00 -0.97 -1.05
W2 818 573 245 13.12 13.25 12.83 4.99 5.06 4.82 -0.03 -0.07 0.07 -1.03 -1.00 -1.12
W3 651 454 197 12.99 13.29 12.29 4.94 4.96 4.85 0.04 0.00 0.14 -0.95 -0.97 -0.90
Symbol search W1 1024 719 305 24.71 25.06 23.90 6.40 6.19 6.80 -0.09 -0.03 -0.14 0.82 0.13 1.81
W2 817 572 245 24.52 24.78 23.92 6.22 6.13 6.38 -0.31 -0.28 -0.36 0.70 0.64 0.75
W3 649 453 196 24.55 25.45 22.49 6.48 6.15 6.77 -0.22 -0.23 -0.05 0.73 0.28 1.59
Age W1 1028 722 306 69.53 69.53 69.54 0.83 0.82 0.85 -0.04 -0.05 0.00 -0.88 -0.86 -0.94
W2 820 575 245 72.49 72.49 72.48 0.71 0.70 0.73 0.00 -0.03 0.06 -0.83 -0.77 -0.98
W3 659 459 200 76.24 76.22 76.29 0.67 0.67 0.69 -0.05 -0.06 -0.02 -0.84 -0.70 -1.15
Number of
medical
conditions
W1 1020 719 301 1.64 2.89 2.88 1.64 1.66 1.58 0.49 0.54 0.34 0.19 0.24 -0.01
W2 820 575 245 1.72 3.29 3.51 1.72 1.70 1.74 0.42 0.35 0.56 0.09 -0.33 0.87
W3 652 453 199 1.76 3.89 3.94 1.76 1.78 1.70 0.48 0.33 0.88 0.42 -0.04 1.57
Dep. symptoms W1 1023 718 305 2.79 2.84 2.68 2.22 2.20 2.28 1.35 1.20 1.66 2.36 1.40 4.40
Neuroticism
parcel
1 912 639 273 2.13 2.14 2.11 0.83 0.81 0.88 0.59 0.50 0.76 -0.12 -0.25 0.07
2 911 639 272 2.61 2.62 2.58 0.81 0.78 0.87 0.24 0.21 0.32 -0.15 -0.20 -0.16
3 912 639 273 2.43 2.45 2.40 0.79 0.78 0.81 0.18 0.13 0.29 -0.37 -0.41 -0.30
Allostatic load W1 1020 716 304 0.74 0.74 0.74 0.25 0.24 0.26 0.99 0.88 1.18 1.76 1.59 1.99
Neuroticism
facet parcels
Dep 912 639 273 2.21 2.20 2.22 0.88 0.86 0.94 0.48 0.40 0.61 -0.32 -0.47 -0.17
Anx 911 639 272 2.73 2.75 2.69 0.86 0.84 0.90 0.13 0.14 0.12 -0.38 -0.40 -0.39
Ang 765 530 235 2.47 2.51 2.39 0.86 0.86 0.86 0.22 0.13 0.45 -0.76 -0.89 -0.36
Females Males
512 369 143 516 353 163
W1 = Wave 1. W2 = Wave 2. W3 = Wave 3. Dep. symptoms = depressive symptoms. Dep = depression. Anx = anxiety. Ang = anger.
https://doi.org/10.1371/journal.pone.0192604.t001
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Main effect of APOE genotype
Satorra-Bentler chi-square tests of the main effect of APOE genotype are in Table 2. Note that
another study using this sample found that APOE E4 carriers had a lower level of initial cogni-
tive ability and greater cognitive decline [49]. In the present study, the initial level of cognitive
ability was 0.18 SD lower (SE = 0.078) in E4 carriers than non-carriers. There was not a statisti-
cally significant difference between groups in the amount of cognitive change. Sex, age and
medical conditions were then added to the model as covariates.
Main effects of depressive symptoms, neuroticism and AL
Estimates of the main effects of depressive symptoms, neuroticism and AL on cognitive ability
and decline, along with tests of the moderation of these effects, are in Table 3. As constraining
the regressions of the cognitive growth factors on depressive symptoms, neuroticism and AL
Table 2. Tests of the Measurement Invariance of the Growth Factors in Groups of APOE E4 Non-carriers and Carriers.
Growth factor means constrained to be equal χ2SB (Δχ
2
SB) df (Δχ2SB df) Δχ2SB p RMSEA SRMR
None 517.58 (N/A) 192 (N/A) N/A .057 .068
Intercept 522.46 (4.84) 193 (1) .028 .058 .070
Slope 521.14 (3.73) 193 (1) .054 .058 .069
N = 1027. Non-E4 carriers group n = 721. E4 carriers group n = 306. All χ2SB ps < .001. SB = Satorra-Bentler. RMSEA = root mean square error of approximation. SRMR
= standardized root mean square residual.
https://doi.org/10.1371/journal.pone.0192604.t002
Table 3. Main Effect and Moderation Tests in Groups of APOE E4 Non-carriers and Carriers.
Predictor Regression
constrained
Regression of intercept on
predictor estimate (SE)
Regression of slope on
predictor estimate (SE)
χ2SB (Δχ
2
SB) df (Δχ2SB df) Δχ2SB p RMSEA SRMR
no E4 group E4 group no E4 group E4 group
Depressive
symptoms
None -0.17
(0.04)
-0.20 (0.07) -0.91
(0.24)
-0.98 (0.65) 789.96 (N/
A)
380 (N/A) N/A .046 .069
Depressive
symptoms
Intercept -0.18
(0.04)
-0.19
(0.04)
-0.91
(0.24)
-0.99 (0.47) 789.88
(0.05)
381 (1) .82 .046 .069
Depressive
symptoms
Slope -0.18
(0.04)
-0.20 (0.07) -0.88 (0.30) -1.00
(0.06)
790.48
(0.21)
381 (1) .644 .046 .069
Neuroticism None -0.25
(0.05)
-0.24
(0.07)
-0.73 (0.67) -0.57 (5.78) 919.86 (N/
A)
472 N/A .043 .065
Neuroticism Intercept -0.24
(0.04)
-0.27
(0.04)
-0.76 (0.59) 0.02 (7.23) 920.10
(0.29)
473 (1) .59 .043 .065
Neuroticism Slope -0.25
(0.05)
-0.23
(0.07)
-0.65 (0.78) -0.91 (1.17) 919.40
(0.00)
473 (1) .83 .043 .065
Allostatic load None -0.10 (0.04) -0.09 (0.07) -0.83 (0.42) -0.98
(0.28)
801.62 (N/
A)
380 (N/A) N/A .046 .071
Allostatic load Intercept -0.10 (0.04) -0.11 (0.04) -0.83 (0.41) -0.98 (0.33) 801.69
(0.08)
381 (1) .77 .046 .071
Allostatic load Slope -0.10 (0.04) -0.09 (0.07) -0.85 (0.36) -0.97 (0.41) 801.40
(0.03)
381 (1) .86 .046 .071
N = 1028. Non-E4 carriers group n = 722. E4 carriers group n = 306. All χ2SB ps < .001. All estimates are standardized. SB = Satorra-Bentler. RMSEA = root mean square
error of approximation. SRMR = standardized root mean square residual.
p .05.
p .01.
p .001.
https://doi.org/10.1371/journal.pone.0192604.t003
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did not worsen fit, main effects were assessed primarily based on the regression coefficients
jointly estimated across groups. Depressive symptoms (E4 non-carriers group [E4-] β [stan-
dardized coefficient] = -0.18, p< .001; E4 carriers group [E4+] β = -0.19, p< .001), neuroti-
cism (E4- β = -0.24, p< .001; E4+ β = -0.27, p< .001) and AL (E4- β = -0.10, p = .005; E4+ β =
-0.11, p = .006) all had small-to-moderate negative associations with the intercept. Depressive
symptoms (E4- β = -0.88, p = .003; E4+ β = -1.00, p< .001) and AL (E4- β = -0.85, p = .018; E4
+ β = -0.97, p = .019) were strongly related to the slope. Standard errors for the effect of neurot-
icism on the slope were large and this parameter was never statistically significant.
Moderation of the effects of depressive symptoms, neuroticism and AL
Satorra-Bentler scaled chi-square tests, which compared models where the effects of depressive
symptoms, neuroticism and AL were and were not constrained to equality across groups, were
all non-significant. This suggested that none of the associations of depressive symptoms, neu-
roticism and AL with the intercept and slope were moderated by APOE E4 status. The absence
of moderation was also supported by the RMSEA and SRMR statistics, which suggested model
fit was near-identical for models with and without regression constraints.
Tests of mediation and moderated mediation
Lastly, models testing whether the association between neuroticism and cognitive ability and
decline was mediated through AL were fitted. Parameter estimates from these models are in
Table 4. Tests of mediation and moderation in the mediation models are in Table 5. All esti-
mates of indirect effects were small and not statistically significant. Satorra-Bentler scaled chi-
square tests were non-significant, which suggested that the paths from AL to the cognitive
intercept and slope were not moderated by APOE E4 status. A lack of moderation was also
indicated by the RMSEA and SRMR model statistics, which were identical to three decimal
places in mediation models with and without regression constraints.
Main effects in mediation models. In the mediation models, neuroticism had a statisti-
cally significant small-to-moderate negative association with the intercept. Standard errors for
estimates of the effect of neuroticism on the slope were large and this parameter was not signifi-
cant in any mediation models. Neuroticism did not significantly predict AL in either group in
any model. When the regression of the intercept on AL was jointly estimated, AL had a small
significant negative association with the intercept in both groups. When the regression of the
slope on AL was jointly estimated, AL significantly predicted the slope in the E4 carriers group.
Robustness checks
The only notable difference between the main model and robustness check model results was
that constraining the intercept growth factor means to be equal in the APOE E4 status groups
did not cause a statistically significant decrement in fit when the aforementioned participants
were excluded: Δχ2SB(1, N = 1002) = 3.39, p = .066. In concordance with the main model
results, Satorra-Bentler scaled chi-square tests indicated that the effects of neuroticism, depres-
sive symptoms and AL on cognitive ability and decline were not moderated by APOE genotype
in these models. Parameter estimates and their statistical significance did not systematically
differ between the main and robustness check models.
Models controlling for education
Full tables of results can be found in S4 Appendix (Tables N-P). The average years of education
were similar across the groups of APOE E4 non-carriers (M [SD] = 10.74 [1.10], Mdn = 10,
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range = 8–13, skew = 0.79, kurtosis = -0.41) and carriers (M [SD] = 10.74 [1.19], Mdn = 10,
range = 7–14, skew = 0.71, kurtosis = -0.16).
Overall, the results from these models were similar to the results from models without edu-
cation as a covariate. Most notably, the effects of depressive symptoms, neuroticism and AL on
baseline cognitive ability tended to be attenuated by around 20–30% (maximum Δ = 0.07).
Consequently, the effect of AL on baseline cognitive ability only remained statistically signifi-
cant in the model in which this regression was jointly estimated across groups. Also, in the
non-E4 carriers group, there were large attenuations for the regressions of cognitive change on
depressive symptoms (maximum Δ = 0.39) and AL (maximum Δ = 0.41), while in the E4 carri-
ers group, the standard errors tended to be much larger for all effects on cognitive change.
This meant that with one exception, these effects were no longer statistically significant. In the
mediation models, estimates for the regression of AL on neuroticism were very similar, but
this path did become statistically significant in the E4 non-carriers group in each model.
Crucially, like in models without education as a covariate, APOE E4 status did not moderate
the effects of depressive symptoms, neuroticism and AL on baseline cognitive ability and sub-
sequent cognitive decline. Plus, importantly, AL did not mediate the effects of neuroticism on
cognitive ability and decline.
Discussion
The current study sought to test five research questions on the relationships depressive symp-
toms, neuroticism and AL have with baseline cognitive ability and subsequent cognitive
decline. The first two of these questions replicated previously reported main effects. At
Table 4. Parameter Estimates from the Mediation Model in Groups of APOE E4 Non-carriers and Carriers.
Regression constrained to
equality
Intercept on N est. (SE) Slope on N est. (SE) AL on N est. (SE) Intercept on AL est. (SE) Slope on AL est. (SE)
no E4 group E4 group no E4
group
E4 group no E4
group
E4 group no E4
group
E4 group no E4
group
E4 group
None -0.24
(0.05)
-0.23
(0.07)
-0.44
(0.59)
-0.10
(1.43)
0.08 (0.04) 0.08
(0.07)
-0.09
(0.04)
-0.07
(0.06)
-0.72
(0.47)
-0.98
(0.23)
Intercept on AL -0.24
(0.05)
-0.23
(0.07)
-0.43
(0.58)
-0.11
(1.55)
0.08 (0.04) 0.08
(0.07)
-0.09
(0.04)
-0.09
(0.04)
-0.73
(0.45)
-0.98
(0.28)
Slope on AL -0.24
(0.05)
-0.23
(0.07)
-0.41
(0.57)
-0.14
(1.86)
0.08 (0.04) 0.08
(0.07)
-0.09
(0.04)
-0.07
(0.07)
-0.75
(0.41)
-0.96 (0.38)
N = 1028. Non-E4 carriers group n = 722. E4 carriers group n = 306. All estimates are standardized. N = neuroticism. AL = allostatic load.
p .05.
p .01.
p .001.
https://doi.org/10.1371/journal.pone.0192604.t004
Table 5. Tests of Mediation and Moderated Mediation in Groups of APOE E4 Non-carriers and Carriers.
Regression constrained to equality Indirect effect on intercept est.
(SE)
Indirect effect on slope est.
(SE)
χ2SB (Δχ
2
SB) df (Δχ2SB df) Δχ2SB p RMSEA SRMR
no E4 group E4 group no E4 group E4 group
None -0.007 (0.005) -0.006 (0.007) -0.056 (0.049) -0.078 (0.070) 962.84 (N/A) 508 (N/A) N/A .042 .063
Intercept on AL -0.006 (0.004) -0.007 (0.007) -0.058 (0.048) -0.076 (0.070) 962.92 (0.10) 509 (1) .75 .042 .063
Slope on AL -0.007 (0.005) -0.006 (0.007) -0.059 (0.046) -0.076 (0.071) 962.44 (0.04) 509 (1) .85 .042 .063
N = 1028. Non-E4 carriers group n = 722. E4 carriers group n = 306. All ns for E4 carriers group = 306. All χ2SB ps < .001. All estimates are standardized. SB = Satorra-
Bentler. RMSEA = root mean square error of approximation. SRMR = standardized root mean square residual.
https://doi.org/10.1371/journal.pone.0192604.t005
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baseline, APOE E4 carriers had significantly lower cognitive ability, but the rate of cognitive
decline did not significantly differ between E4 non-carriers and E4 carriers. When fitting these
models, the variance of the slope growth factor had to be constrained to zero, which indicated
that there was very little variability in cognitive change across the sample.
Our study also replicated the relationship between higher AL and greater subsequent cogni-
tive decline. This replication was important because all previous studies on this relationship
used data from the MacArthur Successful Aging Study [46–48]. We also replicated previous
findings that depressive symptoms are related to cognitive decline. Plus, as in previous studies
using this sample, AL [45] and depressive symptoms [52] were linked to contemporaneously
measured cognitive ability. However, we failed to replicate prior findings that the associations
between depressive symptoms and neuroticism and cognitive ability and decline are moder-
ated by APOE E4.
In the current study, we conducted moderated-mediation analyses investigating the
hypothesis that AL mediates associations between neuroticism and cognitive outcomes.
Results from a novel mediation model suggested that the associations of neuroticism with cog-
nitive ability and decline were not mediated through AL. Further, paths in the second stage of
this mediation model, from AL to cognitive ability and decline, were not moderated by APOE
E4. Paths from AL to cognitive ability and decline were also not moderated by APOE E4 in
models without neuroticism.
Given the varied findings in this and other studies, it is important to consider the features
that differentiate the studies as these may explain the differences in results. With respect to the
moderating effect of APOE E4 status, an important between-study variable is the measurement
of key phenotypes. Studies that have used multiple cognitive tests and non-dichotomous
depressive symptomatology measures have tended not to find the interaction (the present
study, [22, 23]; cf. [21]), whereas those that have used a cognitive impairment screener or clini-
cal diagnosis of cognitive impairment along with a dichotimization or clinical diagnosis of
depressive symptomatology have tended to find the interaction [12–18]. Our study also con-
trasts with most of those that have found the interaction in that depression, MCI and dementia
were not prevalent in our sample, and the cognitive decline observed was not substantial. It
may be, then, that APOE E4 moderates the influence of depressive symptomatology on patho-
logical but not non-pathological cognitive aging. This would have implications for future
research in this area and how research would inform clinical practice.
With regard to the interaction of neuroticism and APOE E4, Dar-Nimrod et al. [25, 26]
measured cognitive ability using a cognitive impairment test and found that APOE moderated
the influence of neuroticism on cognitive ability. This also contrasts with the cognitive ability
measurement and findings of the present study. Results from other studies on the APOE-by-
neuroticism interaction suggest that the specific cognitive domains studied should also be con-
sidered. Sapkota et al. found the APOE-by-neuroticism interaction did not predict baseline or
subsequent change in declarative memory [24]. Chapman et al. found an overall APOE-by-
neuroticism interaction in a multivariate analysis of variance with five cognitive domains as
outcomes [27]. However, the interaction was only statistically significant for one specific
domain: attention [27].
In the current study, we operationalized cognitive ability using multiple tests and a latent
variable modeling perspective. However, these tests were largely executive functioning tasks,
and thus our test battery did not contain many tests tapping, for example, memory perfor-
mance. To the extent that cognitive screening tools cover more aspects of cognition in a more
general way, it may be that results differing results suggest pathways of impact via specific
abilities.
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Consistent with the findings of the main models, in models that controlled for the effect of
education on baseline cognitive ability and decline, APOE E4 did not moderate any effects and
AL did not mediate the relationships neuroticism had with cognitive ability and decline. Main
effects on baseline cognitive ability and cognitive decline were attenuated in these models,
which suggested that education’s prediction of cognitive outcomes in older age may overlap
with that of neuroticism, depressive symptoms and AL. We chose not to control for education
in our main models because it is strongly related to early life cognitive ability, which itself is
strongly related to older age cognitive ability [78]. Controlling for education, therefore,
changed the interpretation of the focal parameters, meaning these models answered research
questions that were somewhat different to those we set out to answer.
The ideal design for a future longitudinal study into this interaction would include compre-
hensive and multifaceted measures of depressive symptomatology and cognitive ability, along
with clinical diagnoses of depression and cognitive disorders. This would enable the interac-
tion to be simultaneously assessed in relation to both healthy and pathological cognitive aging.
For adequate statistical power, a larger sample of MCI and dementia cases would be required
than were present in the current study’s sample. In addition, researchers could collect further
data to investigate potential mechanisms, such as mediators in the brain. It is possible that the
interaction functions through depressive symptoms leading to increased amyloid-beta plaques
[79] and/or decreased hippocampal volume [80], and these effects in the brain are then have
stronger negative associations with worse cognitive ability in E4 allele carriers [81, 82].
This study also found that the association between neuroticism and cognitive ability was
not mediated through AL as has previously been proposed in the literature. In these mediation
models, neuroticism was not linked to AL, except in the additional models where education
was added as a covariate. The present study is one of the first to relate AL and a personality
domain. A previous study found that in models with demographic covariates, AL had a small
positive effect on baseline neuroticism but did not predict subsequent four-year change in neu-
roticism [40]. The relationships between AL and personality factors may prove an interesting
area for future research. All mediation models suggested that, in this sample, AL does not
mediate the relationships neuroticism has with cognitive ability and decline.
The index of AL used here consisted of biomarkers related to inflammation and metabo-
lism, so "inflammatory and metabolic processes" ([25], p. 1152] seem to be an unlikely mecha-
nistic mediator explaining Dar-Nimrod et al.’s [25, 26] APOE-by-neuroticism interaction.
However, the present study was unable to test a potential pathway through HPA axis dysregu-
lation given the biomarkers used to construct our measure of AL. Thus, such a pathway
remains a possibility. A future investigation could test this study’s mediation model with corti-
sol replacing AL, because this particular biomarker has been related to neuroticism [36] and
its associations with cognitive ability [41] and decline [42] have been found to be moderated
by APOE E4 status.
In general, it is important to consider what processes and systems are reflected by measures
of AL, and to what extent the variance in them is preserved. As noted, here the measure of AL
did not contain any HPA axis markers, and so results must be considered in light of this. A
strength of the AL operationalization used was that the z score sum method better preserves
variance than the more commonly used sample quantile-based operationalizations [31]. A cru-
cial step in integrating the growing body of research utilising the AL framework will be a com-
prehensive study of the impact of different biomarker sets and scoring methods.
A strength of this study is that groups based on both APOE E4 status and specific APOE
genotypes were used. Plus, using SEM enabled error-free measurement of neuroticism and
general cognitive ability. However, the availability of only three waves of data precluded the
modeling of non-linear change and limited the statistical power to detect influences on and
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group differences in the slope growth factor. Here, cognitive ability was the only construct
modeled longitudinally. Future research could also model depressive symptoms, neuroticism
and AL data longitudinally. This would enable testing of the moderation of relationships
between change in cognitive ability and change in depressive symptoms, neuroticism and AL.
Another limitation of the present study is that no item- or subscale-level data were available
for depressive symptoms. This meant that error-free measurement of depressive symptoms
and tests focusing on facets of depression, like those performed by Rajan et al. [21], were not
possible. Where possible, future studies on this topic should also investigate the moderation of
relationships at the facet level of depression and neuroticism.
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